Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes. Falconi, G., Fabiani, E., Piciocchi, A., Criscuolo, M., Fianchi, L., Lindfors Rossi, E. L., Finelli, C., Cerqui, E., Ottone, T., Molteni, A., Parma, M., Santarone, S., Candoni, A., Sica, S., Leone, G., Lo-Coco, F., & Voso, M. T. Leukemia, 33(3):785–790, October, 2018.
Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes [link]Paper  doi  bibtex   2 downloads  
@article{falconi_somatic_2018,
	title = {Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes},
	volume = {33},
	copyright = {2018 The Author(s)},
	issn = {1476-5551},
	url = {https://www.nature.com/articles/s41375-018-0284-9},
	doi = {10.1038/s41375-018-0284-9},
	language = {en},
	number = {3},
	urldate = {2020-02-11},
	journal = {Leukemia},
	author = {Falconi, Giulia and Fabiani, Emiliano and Piciocchi, Alfonso and Criscuolo, Marianna and Fianchi, Luana and Lindfors Rossi, Elisa L. and Finelli, Carlo and Cerqui, Elisa and Ottone, Tiziana and Molteni, Alfredo and Parma, Matteo and Santarone, Stella and Candoni, Anna and Sica, Simona and Leone, Giuseppe and Lo-Coco, Francesco and Voso, Maria Teresa},
	month = oct,
	year = {2018},
	keywords = {Allogeneic Stem Cell Transplantation, Clinical study, Genomics, Liquid tumor, MDS, MYS, Myelodysplastic syndromes, Somatic Mutations},
	pages = {785--790},
}

Downloads: 2